AZD8529 Multiple Ascending Dose Study in Healthy Subjects

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: October 2, 2008
Last updated: June 25, 2009
Last verified: June 2009

This is a study to evaluate safety, tolerability, PK and PD effects of orally administered AZD8529 after multiple ascending doses

Condition Intervention Phase
Healthy Volunteer
Drug: AZD8529
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8529 When Given as Single and Multiple Ascending Oral Doses in Healthy Subjects

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To assess the safety and tolerability of multiple dose administration of AZD8529 when given orally to healthy male subjects and female subjects of non-childbearing potential. [ Time Frame: each visit, at least daily, during the study. ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To characterize the pharmacokinetics of AZD8529 in plasma [ Time Frame: Blood samples will be taken during the study. ] [ Designated as safety issue: No ]

Estimated Enrollment: 47
Study Start Date: October 2008
Study Completion Date: March 2009
Arms Assigned Interventions
Experimental: 1 Drug: AZD8529
Placebo Comparator: 2 Drug: Placebo


Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Female subjects must be of non-child bearing potential.

Exclusion Criteria:

  • Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 30months of the first administration of investigational prod
  • Plasma donation within one month of screening or any blood donation/blood loss > 500mL during the 3 months prior to screening
  • Clinically relevant abnormalities in physical examinations, vital signs, ECG, clinical chemistry, hematology or urinalysis
  Contacts and Locations
Please refer to this study by its identifier: NCT00765492

Sponsors and Collaborators
Study Director: Mark Smith, MD, PhD AstraZeneca
  More Information

No publications provided

Responsible Party: Mark A. Smith, MD; Medical Science Director, AstraZeneca Identifier: NCT00765492     History of Changes
Other Study ID Numbers: D1960C00002
Study First Received: October 2, 2008
Last Updated: June 25, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
Phase I processed this record on April 15, 2014